• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Keratin 17 Is a Novel Cytologic Biomarker for Urothelial Carcinoma Diagnosis.角蛋白 17 是一种用于诊断尿路上皮癌的新型细胞学生物标志物。
Am J Clin Pathol. 2021 Oct 13;156(5):926-933. doi: 10.1093/ajcp/aqab050.
2
Keratin 17 is a sensitive and specific biomarker of urothelial neoplasia.角蛋白 17 是尿路上皮肿瘤的一种敏感且特异的生物标志物。
Mod Pathol. 2019 May;32(5):717-724. doi: 10.1038/s41379-018-0177-5. Epub 2018 Nov 15.
3
[Value of CK20 immunocytochemistry as an adjuvant to urine liquid-based cytology in detection of urothelial carcinoma].[细胞角蛋白20免疫细胞化学作为尿液液基细胞学辅助手段在检测尿路上皮癌中的价值]
Zhonghua Zhong Liu Za Zhi. 2012 Sep;34(9):669-73. doi: 10.3760/cma.j.issn.0253-3766.2012.09.006.
4
ImmunoCyt and cytokeratin 20 immunocytochemistry as adjunct markers for urine cytologic detection of bladder cancer: a prospective study.免疫细胞化学和细胞角蛋白20免疫细胞化学作为膀胱癌尿液细胞学检测的辅助标志物:一项前瞻性研究。
Anal Quant Cytol Histol. 2010 Feb;32(1):45-52.
5
Combined application of cytology and molecular urine markers to improve the detection of urothelial carcinoma.联合细胞学和分子尿液标志物应用以提高尿路上皮癌的检测率。
Cancer Cytopathol. 2013 May;121(5):252-60. doi: 10.1002/cncy.21247. Epub 2012 Nov 21.
6
The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer--institutional experience and review.尿核基质蛋白22(NMP22)作为尿液细胞学检查的辅助诊断手段用于监测复发性膀胱癌的机构经验及综述
Diagn Cytopathol. 2015 Apr;43(4):307-14. doi: 10.1002/dc.23239. Epub 2014 Dec 8.
7
Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma.用于排除复发性尿路上皮癌的非侵入性尿液检测的临床比较
Urol Oncol. 2017 Aug;35(8):531.e15-531.e22. doi: 10.1016/j.urolonc.2017.03.008. Epub 2017 Mar 31.
8
Cytokeratin 20 immunocytochemistry on urine sediments: A potential low-cost adjunct to cytology in the diagnosis of low-grade urothelial carcinoma.尿沉渣细胞角蛋白20免疫细胞化学:一种用于诊断低级别尿路上皮癌的潜在低成本细胞学辅助方法。
Cytopathology. 2017 Dec;28(6):531-535. doi: 10.1111/cyt.12463. Epub 2017 Sep 22.
9
Immunocytochemical staining for p53 and Ki-67 helps to characterise urothelial cells in urine cytology.对p53和Ki-67进行免疫细胞化学染色有助于在尿液细胞学中对尿路上皮细胞进行特征描述。
Cytopathology. 2016 Dec;27(6):456-464. doi: 10.1111/cyt.12332. Epub 2016 Mar 8.
10
Predictive value of MCM5 (ADXBLADDER) analysis in urine of men evaluated for the initial diagnosis of bladder cancer: A comparative prospective study.MCM5(ADXBLADDER)分析在男性膀胱癌初始诊断评估中的预测价值:一项比较性前瞻性研究。
Diagn Cytopathol. 2020 Nov;48(11):1034-1040. doi: 10.1002/dc.24530. Epub 2020 Jun 20.

引用本文的文献

1
Cytokeratin 17 activates AKT signaling to induce epithelial-mesenchymal transition and promote bladder cancer progression.细胞角蛋白17激活AKT信号传导以诱导上皮-间质转化并促进膀胱癌进展。
BMC Urol. 2025 Apr 7;25(1):77. doi: 10.1186/s12894-025-01760-4.
2
Acu-URO17 is a highly sensitive and specific bladder cancer biomarker.Acu-URO17是一种高度敏感且特异的膀胱癌生物标志物。
BJUI Compass. 2024 Feb 29;5(5):497-501. doi: 10.1002/bco2.338. eCollection 2024 May.
3
Current look at the most promising proteomic and glycomic biomarkers of bladder cancer.当前对膀胱癌最有前途的蛋白质组学和糖组学生物标志物的研究。
J Cancer Res Clin Oncol. 2024 Feb 19;150(2):96. doi: 10.1007/s00432-024-05623-7.
4
Molecular Markers for Bladder Cancer Screening: An Insight into Bladder Cancer and FDA-Approved Biomarkers.膀胱癌筛查的分子标志物:对膀胱癌和 FDA 批准的生物标志物的深入了解。
Int J Mol Sci. 2023 Sep 21;24(18):14374. doi: 10.3390/ijms241814374.
5
Scoring Systems for Immunohistochemistry in Urothelial Carcinoma.尿路上皮癌免疫组织化学评分系统
Methods Mol Biol. 2023;2684:3-25. doi: 10.1007/978-1-0716-3291-8_1.
6
"In the light of evolution:" keratins as exceptional tumor biomarkers.从进化角度来看:角蛋白作为一种特殊的肿瘤标志物。
PeerJ. 2023 Mar 17;11:e15099. doi: 10.7717/peerj.15099. eCollection 2023.
7
Alterations of Cytoskeleton Networks in Cell Fate Determination and Cancer Development.细胞命运决定和癌症发生中的细胞骨架网络改变。
Biomolecules. 2022 Dec 13;12(12):1862. doi: 10.3390/biom12121862.
8
Proteomics for Early Detection of Non-Muscle-Invasive Bladder Cancer: Clinically Useful Urine Protein Biomarkers.蛋白质组学用于非肌层浸润性膀胱癌的早期检测:具有临床应用价值的尿液蛋白质生物标志物
Life (Basel). 2022 Mar 9;12(3):395. doi: 10.3390/life12030395.
9
Biomarkers in Bladder Cancer Surveillance.膀胱癌监测中的生物标志物
Front Surg. 2021 Sep 28;8:735868. doi: 10.3389/fsurg.2021.735868. eCollection 2021.

本文引用的文献

1
Reclassification of urinary cytology regarding The Paris System for Reporting Urinary Cytology with cytohistological correlation demonstrates high sensitivity for high-grade urothelial carcinoma.关于《巴黎泌尿系统细胞学报告系统》并结合细胞组织学相关性对泌尿系统细胞学进行重新分类,显示出对高级别尿路上皮癌具有高敏感性。
Diagn Cytopathol. 2020 May;48(5):446-452. doi: 10.1002/dc.24387. Epub 2020 Jan 24.
2
Impact of the Paris system for reporting urine cytopathology on predictive values of the equivocal diagnostic categories and interobserver agreement.巴黎尿液细胞病理学报告系统对可疑诊断类别的预测价值及观察者间一致性的影响
Cytojournal. 2019 Oct 22;16:21. doi: 10.4103/cytojournal.cytojournal_30_19. eCollection 2019.
3
Keratin 17 is a negative prognostic biomarker in high-grade endometrial carcinomas.角蛋白 17 是高级别子宫内膜癌的预后不良生物标志物。
Hum Pathol. 2019 Dec;94:40-50. doi: 10.1016/j.humpath.2019.09.005. Epub 2019 Oct 23.
4
The Paris System for reporting urinary cytology in daily practice with emphasis on ancillary testing by multiprobe FISH.巴黎系统在日常实践中报告尿细胞学,重点是通过多探针 FISH 进行辅助检测。
J Clin Pathol. 2020 Feb;73(2):90-95. doi: 10.1136/jclinpath-2019-206109. Epub 2019 Aug 29.
5
Keratin 17 identifies the most lethal molecular subtype of pancreatic cancer.角蛋白 17 可鉴定出胰腺癌最致命的分子亚型。
Sci Rep. 2019 Aug 2;9(1):11239. doi: 10.1038/s41598-019-47519-4.
6
A Quest for Accuracy: Evaluation of The Paris System in Diagnosis of Urothelial Carcinomas.对准确性的探索:巴黎系统在尿路上皮癌诊断中的评估
J Cytol. 2019 Jul-Sep;36(3):169-173. doi: 10.4103/JOC.JOC_67_18.
7
Cancer statistics, 2019.癌症统计数据,2019 年。
CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.
8
Keratin 17 is a sensitive and specific biomarker of urothelial neoplasia.角蛋白 17 是尿路上皮肿瘤的一种敏感且特异的生物标志物。
Mod Pathol. 2019 May;32(5):717-724. doi: 10.1038/s41379-018-0177-5. Epub 2018 Nov 15.
9
The diagnostic accuracy of methylation markers in urine for the detection of bladder cancer: a systematic review.尿液甲基化标志物诊断膀胱癌的准确性:系统评价。
Epigenomics. 2018 May;10(5):673-687. doi: 10.2217/epi-2017-0156. Epub 2018 Apr 25.
10
Bladder Cancer: Diagnosis and Treatment.膀胱癌:诊断与治疗
Am Fam Physician. 2017 Oct 15;96(8):507-514.

角蛋白 17 是一种用于诊断尿路上皮癌的新型细胞学生物标志物。

Keratin 17 Is a Novel Cytologic Biomarker for Urothelial Carcinoma Diagnosis.

机构信息

Department of Pathology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, USA.

Program of Public Health and Department of Preventative Medicine, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, USA.

出版信息

Am J Clin Pathol. 2021 Oct 13;156(5):926-933. doi: 10.1093/ajcp/aqab050.

DOI:10.1093/ajcp/aqab050
PMID:34086841
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8512275/
Abstract

OBJECTIVES

The microscopic features of urine cytology specimens are subjective and may not reliably distinguish between benign urothelial cells and low-grade urothelial carcinoma (UC). Prior studies demonstrated that keratin 17 (K17) detection in biopsies is highly sensitive for UC. The current study aimed to define K17 diagnostic test performance for initial screening and detect recurrent UC in urine specimens.

METHODS

K17 was detected by immunocytochemistry (ICC) in consecutively collected urine specimens (2018-2019). A qualitative score for the K17 test was determined in 81 samples (discovery cohort) and validated in 98 samples (validation cohort). K17 sensitivity and specificity were analyzed in both cohorts across all grades of UC.

RESULTS

Based on the discovery cohort, the presence of 5 or more K17 immunoreactive urothelial cells (area under the curve = 0.90; P < .001) was the optimal threshold to define a K17-positive test. The sensitivity of the K17 ICC test for biopsy-confirmed UC was 35 of 36 (97%) and 18 of 21 (86%) in the discovery and validation cohorts, respectively. K17 was positive in 16 of 19 (84%) specimens with biopsy-confirmed low-grade UC and in 34 of 34 (100%) of specimens with high-grade UC.

CONCLUSIONS

K17 ICC is a highly sensitive diagnostic test for initial screening and detection of recurrence across all grades of UC.

摘要

目的

尿细胞学标本的微观特征具有主观性,可能无法可靠地区分良性尿路上皮细胞和低级别尿路上皮癌(UC)。先前的研究表明,活检中角蛋白 17(K17)的检测对 UC 具有高度敏感性。本研究旨在确定 K17 诊断测试在初始筛选中的性能,并检测尿液标本中的复发性 UC。

方法

连续收集尿标本(2018-2019 年)进行免疫细胞化学(ICC)检测 K17。在 81 个样本(发现队列)中确定 K17 检测的定性评分,并在 98 个样本(验证队列)中进行验证。分析了两个队列中所有级别 UC 的 K17 敏感性和特异性。

结果

基于发现队列,存在 5 个或更多 K17 免疫反应性尿路上皮细胞(曲线下面积=0.90;P<0.001)是定义 K17 阳性测试的最佳阈值。K17 ICC 测试对活检证实的 UC 的敏感性在发现队列和验证队列中分别为 36 例中的 35 例(97%)和 21 例中的 18 例(86%)。在活检证实的低级别 UC 的 19 个标本中有 16 个(84%)和高级别 UC 的 34 个标本中 34 个(100%)标本 K17 阳性。

结论

K17 ICC 是一种高度敏感的诊断测试,可用于初始筛选和检测所有级别的 UC 复发。